Mon, 15th Jun 2020 15:44
NetScientific PLC - Ashford-based healthcare IP commercialisation firm - Says portfolio firm PDS Biotechnology Corp begins Phase 2 clinical study of PDS0101 cancer medication. Net Scientific owns 7.2% stake in PDS.
Current stock price: 6.40 pence
Year-to-date change: down 5.2%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
(Alliance News) - NetScientific PLC on Monday said its portfolio company ProAxsis Ltd secured GBP1.8 million in investment.
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
(Alliance News) - NetScientific PLC on Wednesday released a portfolio and strategy update.
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
NetScientific PLC - technology and life sciences investor - Portfolio company DeepTech Recycling Ltd closes GBP1 million fundraising. DeepTech, in whi...
Netscientific (NSCI)